Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented. PATIENTS AND METHODS: We systematically searched research databases, conference abstracts and trial registries for any studies reporting cancer outcomes for individual tumour types in metformin users compared with non-users, and extracted data on patients with early-stage cancer. Studies were assessed for design and quality, and a meta-analysis was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS), to inform future trial design. RESULTS: Of 7670 articles screened, 27 eligible studies were identified comprising 24 178 participants, all enrolled in observational studies. In those with early-stage colorectal cancer, metformin use was associated with a significant benefit in all outcomes [RFS hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.47-0.85; OS HR 0.69, CI 0.58-0.83; CSS HR 0.58, CI 0.39-0.86]. For men with early-stage prostate cancer, metformin was associated with significant, or borderline significant, benefits in all outcomes (RFS HR 0.83, CI 0.69-1.00; OS HR 0.82, CI 0.73-0.93; CSS HR 0.58, CI 0.37-0.93); however, there was significant heterogeneity between studies. The data suggest that prostate cancer patients treated with radical radiotherapy may benefit more from metformin (RFS HR 0.45, CI 0.29-0.70). In breast and urothelial cancer, no significant benefits were identified. Sufficient data were not available to conduct analyses on the impact of metformin dose and duration. CONCLUSIONS: Our findings suggest that metformin could be a useful adjuvant agent, with the greatest benefits seen in colorectal and prostate cancer, particularly in those receiving radical radiotherapy, and randomised, controlled trials which investigate dose and duration, alongside efficacy, are advocated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2014) · Medical Entomology and Zoology · Cited by 17,633
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Burn, J., Gerdes, A.-M., Macrae, F., Mecklin, J.-P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61049-0 · Cited by 952
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933 · cited 2×
“The effect of metformin on AMPK signalling has been hypothesised to be a major pathway through which metformin exerts its anti-cancer effects [10].”
BackgroundMetformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
AMPK, insulin resistance, and the metabolic syndrome
Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67227 · Cited by 873
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Aggregate data meta‐analysis with time‐to‐event outcomes
Williamson, P. R., Smith, C. T., Hutton, J. L., & Marson, A. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1303 · Cited by 551
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
Metabolic syndrome, hyperinsulinemia, and colon cancer: a review
Giovannucci, E. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.836s · Cited by 531
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466 · cited 1×
“While the advanced setting can provide a sufficient event rate, there is evidence to suggest that metformin requires long-term use to exert its anti-cancer effect [78], and therefore, patients with established cancer with more limited prognoses may not be able to receive metformin long enough for a therapeutic benefit…”
BackgroundQuaresma, M., Coleman, M. P., & Rachet, B. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61396-9 · Cited by 461
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Understanding the benefit of metformin use in cancer treatment
Dowling, R. J., Goodwin, P. J., & Stambolic, V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-33 · Cited by 409
Metformin in cancer: translational challenges
Dowling, R. J. O., Niraula, S., Stambolic, V., & Goodwin, P. J. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0007 · Cited by 355
Higurashi, T., Hosono, K., Takahashi, H., Komiya, Y., Umezawa, S., Sakai, E., Uchiyama, T., Taniguchi, L., Hata, Y., Uchiyama, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00565-3 · Cited by 331
Cook, N. R., Lee, I.-M., Zhang, S. M., Moorthy, M. V., & Buring, J. E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00002 · Cited by 315
Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Zannella, V. E., Dal Pra, A., Muaddi, H., McKee, T. D., Stapleton, S., Sykes, J., Glicksman, R., Chaib, S., Zamiara, P., Milosevic, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1787 · Cited by 314
Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., Suzuki, K., Iida, H., Sakamoto, Y., Yoneda, K., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0186 · Cited by 311
Hadad, S., Iwamoto, T., Jordan, L., Purdie, C., Bray, S., Baker, L., Jellema, G., Deharo, S., Hardie, D. G., Pusztai, L., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1612-1 · Cited by 293
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., La Vecchia, C., Mancia, G., & Corrao, G. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0462 · Cited by 274
Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes
Margel, D., Urbach, D. R., Lipscombe, L. L., Bell, C. M., Kulkarni, G., Austin, P. C., & Fleshner, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7043 · Cited by 271
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 270
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study
Niraula, S., Dowling, R. J. O., Ennis, M., Chang, M. C., Done, S. J., Hood, N., Escallon, J., Leong, W. L., McCready, D. R., Reedijk, M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2223-1 · Cited by 238
Metformin and breast cancer risk: a meta-analysis and critical literature review
Col, N. F., Ochs, L., Springmann, V., Aragaki, A. K., & Chlebowski, R. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2170-x · Cited by 216
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus
Lee, J. H., Kim, T. I., Jeon, S. M., Hong, S. P., Cheon, J. H., & Kim, W. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.26421 · Cited by 204
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197 · cited 1×
“Additionally, data on the toxicity profile of metformin in those without type II diabetes mellitus (DM) are already available from clinical trials investigating its role as a treatment for polycystic ovarian syndrome [8].”
BackgroundSpratt, D. E., Zhang, C., Zumsteg, Z. S., Pei, X., Zhang, Z., & Zelefsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2012.12.004 · Cited by 180
Bayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176
Metformin is associated with improved survival in endometrial cancer
Ko, E. M., Walter, P., Jackson, A., Clark, L., Franasiak, J., Bolac, C., Havrilesky, L. J., Secord, A. A., Moore, D. T., Gehrig, P. A., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.021 · Cited by 158
Yin, M., Zhou, J., Gorak, E. J., & Quddus, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0111 · Cited by 157
Zhang, Z. ‐., & Li, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12267 · Cited by 149
Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
Langley, R. E., Burdett, S., Tierney, J. F., Cafferty, F., Parmar, M. K. B., & Venning, G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.289 · Cited by 144
Self-citationClarke, M., Brice, A., & Chalmers, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102670 · Cited by 120
Xu, H., Chen, K., Jia, X., Tian, Y., Dai, Y., Li, D., Xie, J., Tao, M., & Mao, Y. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0096 · Cited by 119
Association Between Metformin Therapy and Mortality After Breast Cancer
Lega, I. C., Austin, P. C., Gruneir, A., Goodwin, P. J., Rochon, P. A., & Lipscombe, L. L. (2013) · Diabetes Care · doi:10.2337/dc12-2535 · Cited by 110
Fidan, E., Ersöz, H. Ö., Yılmaz, M., Yilmaz, H., Koçak, M., Karahan, C., & Erem, C. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0276-y · Cited by 107
Park, H. S.-M., Schoenfeld, J. D., Vega, R. B. M., Shive, M. L., Hartman, R. I., Ogembo, R., & Mucci, L. A. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt077 · Cited by 101
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
Lee, C., Jung, M., Jung, I., Heo, S. J., Jeong, Y. H., An, J. Y., Kim, H., Cheong, J., Hyung, W. J., Noh, S. H., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001086 · Cited by 91
A Cohort Study of Metformin Exposure and Survival in Patients with Stage I–III Colorectal Cancer
Spillane, S., Bennett, K., Sharp, L., & Barron, T. I. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0347 · Cited by 91
Mei, Z.-B., Zhang, Z.-J., Liu, C.-Y., Liu, Y., Cui, A., Liang, Z.-L., Wang, G.-H., & Cui, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091818 · Cited by 89
Bosco, C., Crawley, D., Adolfsson, J., Rudman, S., & Van Hemelrijck, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117344 · Cited by 84
Rieken, M., Xylinas, E. N., Kluth, L. A., Crivelli, J. J., Chrystal, J., Faison, T., Lotan, Y., Karakiewicz, P. I., Fajković, H., Babjuk, M., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12448 · Cited by 79
Yu, H., Yin, L., Jiang, X., Sun, X., Wu, J., Tian, H., Gao, X., & He, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116327 · Cited by 77
Jones, A. P., Conroy, E., Williamson, P. R., Clarke, M., & Gamble, C. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-50 · Cited by 72 · cited 1×
“There have been a number of calls for systematic reviews and meta-analyses to be conducted as part of the scientific justification, and to inform the design, of new clinical trials [30, 31].”
BackgroundMetformin and prostate cancer mortality: A meta-analysis
Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0687-0 · Cited by 72 · cited 2×
“Five meta-analyses have examined the effect of metformin on OS [22, 23, 25–27], two of which also investigated prostate CSS [25, 26].”
BackgroundAMPK regulates metabolism and survival in response to ionizing radiation
Zannella, V. E., Cojocari, D., Hilgendorf, S., Vellanki, R. N., Chung, S., Wouters, B. G., & Koritzinsky, M. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.049 · Cited by 71
Shen, Z., Ye, Y., Bin, L., Yin, M., Yang, X., Jiang, K., & Wang, S. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.05.005 · Cited by 68
Raval, A. D., Thakker, D., Vyas, A., Salkini, M., Madhavan, S. S., & Sambamoorthi, U. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.52 · Cited by 67
Effect of metformin on prostate cancer outcomes after radical prostatectomy
Kaushik, D., Karnes, R. J., Eisenberg, M. S., Rangel, L. J., Carlson, R. E., & Bergstralh, E. J. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.05.005 · Cited by 58
Allott, E. H., Abern, M. R., Gerber, L., Keto, C. J., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., Cooperberg, M. R., Moorman, P. G., et al. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.48 · Cited by 58
Impact of Diabetes on Oncologic Outcome of Colorectal Cancer Patients: Colon vs. Rectal Cancer
Jeon, J. Y., Jeong, D. H., Park, M. G., Lee, J., Chu, S. H., Park, J., Lee, M. K., Sato, K., Ligibel, J. A., Meyerhardt, J. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055196 · Cited by 58
Rieken, M., Xylinas, E. N., Kluth, L. A., Crivelli, J. J., Chrystal, J., Faison, T., Lotan, Y., Karakiewicz, P. I., Sun, M., Fajković, H., et al. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.07.006 · Cited by 55
The Effect of Metformin on Mortality Following Cancer among Patients with Diabetes
Lega, I. C., Shah, P. S., Margel, D., Beyene, J., Rochon, P. A., & Lipscombe, L. L. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0327 · Cited by 53
Singh, P. P., Shi, Q., Foster, N. R., Grothey, A. A., Nair, S., Chan, E. W., Shields, A. F., Goldberg, R. M., Gill, S., Kahlenberg, M. S., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0153 · Cited by 53
Zanders, M. M. J., van Herk‐Sukel, M. P. P., Vissers, P. A. J., Herings, R. M. C., Haak, H. R., & van de Poll-Franse, L. V. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.259 · Cited by 50
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes
Oppong, B. A., Pharmer, L. A., Oskar, S., Eaton, A. A., Stempel, M. M., Patil, S. N., & King, T. A. (2014) · Cancer Medicine · doi:10.1002/cam4.259 · Cited by 49
Rieken, M., Kluth, L. A., Xylinas, E. N., Fajković, H., Becker, A., Karakiewicz, P. I., Herman, M. P., Lotan, Y., Seitz, C., Schramek, P., et al. (2013) · World Journal of Urology · doi:10.1007/s00345-013-1171-7 · Cited by 45
Rieken, M., Xylinas, E. N., Kluth, L. A., Trinh, Q., Lee, R. K., Fajković, H., Novara, G., Margulis, V., Lotan, Y., Martínez‐Salamanca, J. I., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.09.016 · Cited by 41
Hakimi, A. A., Chen, L., Kim, P. H., Sjoberg, D. D., Glickman, L., Walker, M. R., & Russo, P. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.1447 · Cited by 37
Psutka, S. P., Boorjian, S. A., Lohse, C. M., Stewart, S. B., Tollefson, M. K., Cheville, J. C., Leibovich, B. C., & Thompson, R. H. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.07.008 · Cited by 36
Danzig, M. R., Kotamarti, S., Ghandour, R. A., Rothberg, M. B., Dubow, B. P., Benson, M. C., Badani, K. K., & McKiernan, J. M. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.47 · Cited by 33
Kwon, M., Roh, J., Song, J., Lee, S.-W., Kim, S., Choi, S., & Nam, S. Y. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0426 · Cited by 27
Taira, A. V., Merrick, G. S., Galbreath, R. W., Morris, M., Butler, W. M., & Adamovich, E. (2014) · Journal of Contemporary Brachytherapy · doi:10.5114/jcb.2014.45757 · Cited by 21
Repurposing Vitamin D as an Anticancer Drug
Gilbert, D. C., Vale, C. L., Haire, R., Coyle, C., & Langley, R. E. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.10.004 · Cited by 15
Self-citationLee, G. E., Aung, T., Lim, K. H., Tan, W. S., Tai, W. M. D., Suhaimi, N.-A. B., Tan, M., & Tan, I. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3589 · Cited by 11
Singh, P. P., Shi, Q., Foster, N. R., Grothey, A. A., Nair, S., Chan, E. W., Shields, A. F., Goldberg, R. M., Gill, S., Kahlenberg, M. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3531 · Cited by 5
Fortune-Greeley, A. K., Williams, C. D., Paulus, J. K., & Kelley, M. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7568 · Cited by 2
Thompson, C. F., Wang, M. B., Sanaiha, Y., Lai, C. P. T., Grogan, T., Elashoff, D. A., & John, M. A. S. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.45109 · Cited by 1
Cited by
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920
“RCTs are also required to evaluate further initial indications that metformin can enhance survival rates among patients with CRC [97].”
BackgroundEnhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Saraei, P., Asadi, I., Kakar, M. A., & Moradi-Kor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 350
Metadata
- Authors
- Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 27
- Issue
- 12
- Pages
- 2184-2195
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2524637936
- Cited by
- 452
- References
- 74
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.